Has Mesoblast’s Surging Share Price Left Its Future Growth Prospects Underappreciated?

Simply Wall St.12-17

If you are wondering whether Mesoblast is a hidden bargain or a value trap at its current share price, you are not alone. This breakdown aims to unpack that question. The stock has been choppy in the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592791957?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2025-12-17 09:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592791957","market":"hk","top_or_hot":-1,"title":"Has Mesoblast’s Surging Share Price Left Its Future Growth Prospects Underappreciated?","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Mesoblast is a hidden bargain or a value trap at its current share price, you are not alone. This breakdown aims to unpack that question. The stock has been choppy in the ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/has-mesoblasts-surging-share-price-left-its-future-growth-pr\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Has Mesoblast’s Surging Share Price Left Its Future Growth Prospects Underappreciated?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHas Mesoblast’s Surging Share Price Left Its Future Growth Prospects Underappreciated?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-17 09:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/has-mesoblasts-surging-share-price-left-its-future-growth-pr><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Mesoblast is a hidden bargain or a value trap at its current share price, you are not alone. This breakdown aims to unpack that question. The stock has been choppy in the ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/has-mesoblasts-surging-share-price-left-its-future-growth-pr\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DCF","symbol_name":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/has-mesoblasts-surging-share-price-left-its-future-growth-pr","article_id":"2592791957","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/has-mesoblasts-surging-share-price-left-its-future-growth-pr","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2592791957","pubTimestamp":1765934210,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Mesoblast is a hidden bargain or a value trap at its current share price, you are not alone. This breakdown aims to unpack that question.\nThe stock has been choppy in the short term, down 1.8% over the last week. That comes after a 24.8% jump over the past month and a 42.8% gain over the last year, all against a still negative year to date return of 17.3% and a 215.8% rise over three years.\nRecent moves have been driven less by day to day noise and more by...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4139":"生物科技","BK7067":"生物科技","BK7508":"医药生物股","BK7501":"新冠治疗股","MSB.AU":"MESOBLAST LTD","MESO":"Mesoblast Limited"},"translate_title":"Mesoblast飙升的股价是否导致其未来增长前景被低估？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MESO":1.5,"DCF":1,"MSB.AU":1},"content_text":"If you are wondering whether Mesoblast is a hidden bargain or a value trap at its current share price, you are not alone. This breakdown aims to unpack that question. The stock has been choppy in the short term, down 1.8% over the last week. That comes after a 24.8% jump over the past month and a 42.8% gain over the last year, all against a still negative year to date return of 17.3% and a 215.8% rise over three years. Recent moves have been driven less by day to day noise and more by shifting expectations around Mesoblast's pipeline progress and regulatory backdrop. Investors are reassessing the likelihood and timing of key approvals. At the same time, broader biotech sentiment and capital flows into higher risk growth names have added extra volatility to every piece of Mesoblast related news. Right now, Mesoblast scores a 4/6 valuation check rating. This suggests the market may not be fully pricing in its potential. However, headline metrics only tell part of the story. Next we will walk through the usual valuation approaches before circling back to a more complete way of thinking about what this stock may be worth.  Mesoblast delivered 42.8% returns over the last year. See how this stacks up to the rest of the Biotechs industry. Approach 1: Mesoblast Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow model estimates what a company might be worth by projecting its future cash flows and discounting them back to today, to reflect risk and the time value of money. For Mesoblast, the latest twelve month Free Cash Flow is roughly $50.7 million in the red, highlighting its current cash burn as it develops its pipeline. Analysts project this to turn positive and scale rapidly, with forecasts reaching about $1.21 billion in Free Cash Flow by 2035, based initially on analyst estimates through 2028 and then extended using Simply Wall St extrapolations for later years. Feeding these cash flow projections into a 2 Stage Free Cash Flow to Equity model produces an estimated intrinsic value of about $26.18 per share. Compared with the current share price, this implies the stock is roughly 89.4% undervalued and suggests a substantial mismatch between projected cash generation and what the market is currently willing to pay. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Mesoblast is undervalued by 89.4%. Track this in your watchlist or portfolio, or discover 910 more undervalued stocks based on cash flows. MSB Discounted Cash Flow as at Dec 2025 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Mesoblast. Approach 2: Mesoblast Price vs Book For asset heavy or still loss making biotechs, the price to book ratio is often a more meaningful starting point than earnings based multiples. This is because it anchors valuation to the net assets funding the pipeline rather than profits that are not yet in sight. In general, faster growing and less risky companies tend to justify a higher normal price to book multiple. Slower growth or higher risk businesses are usually assigned a lower one, as investors demand a discount for the extra uncertainty. Mesoblast currently trades on a price to book of about 3.95x, below the Biotechs industry average of roughly 6.23x and also under the peer group average of around 4.56x. Simply Wall St’s proprietary Fair Ratio framework goes a step further by estimating what a reasonable price to book should be once Mesoblast’s growth prospects, risk profile, margins, industry positioning and market cap are all taken into account, rather than relying on blunt peer comparisons. On that basis, Mesoblast’s actual 3.95x multiple sits below the Fair Ratio estimate, indicating the shares are pricing in more caution than the model suggests is warranted. Result: UNDERVALUED ASX:MSB PB Ratio as at Dec 2025 PB ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1457 companies where insiders are betting big on explosive growth. Upgrade Your Decision Making: Choose your Mesoblast Narrative Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, a simple way to connect your view of a company with the numbers behind its potential. A Narrative is the story you believe about Mesoblast, translated into assumptions about future revenue growth, profit margins and risk, which then flows into a financial forecast and a fair value estimate. On Simply Wall St’s Community page, millions of investors use Narratives as an accessible tool to map their perspective to a clear Buy, Hold or Sell stance by comparing their Fair Value to the current share price. As new information such as trial results, regulatory decisions or earnings updates arrive, these Narratives and their valuations update dynamically, helping you decide whether your story still holds. For example, one Mesoblast Narrative might assume rapid approval and strong commercial uptake with a high fair value, while another might price in slower approval and tougher competition, leading to a much lower fair value and a more cautious stance. Do you think there's more to the story for Mesoblast? Head over to our Community to see what others are saying! ASX:MSB 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Mobile Infrastructure for Defense and DisasterThe next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.Get the investor briefing before the next round of contractsSponsored On Behalf of CiTechNew: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592791957","isCrawlerRequest":true}